Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
acid, Alcon, Allergan, amikacin, Avelox, awarded, Bausch, Bayer, Belgium, Besivance, Capastat, capreomycin, Cipro, ciprofloxacin, competitor, concomitant, CTA, cyclophilin, cycloserine, DAA, Effcon, Eli, Enanta, ethambutol, ethionamide, Europe, field, IIa, immunomodulatory, Importantly, isoniazid, kanamycin, Kantrex, Lilly, Lomb, moxifloxacin, Muldova, Myambutol, NIH, Nydrazid, PASER, pegylated, picomolar, Presidio, pyrazinamide, resource, Rifadin, rifampin, RNA, Sandoz, SBIR, Seromycin, show, strongly, suggest, suited, Teva, Tibotec, Trecator, unexercised, Vigamox, Zymar
Removed:
accomplish, Arpida, banking, Basilea, ceftobiprole, consisted, consulting, Cubicin, dalbavancin, dalfopristin, daptomycin, discovering, Division, doripenem, DSPTP, garenoxacin, headcount, iclaprim, institution, King, linezolid, nosocomial, Ophthalmology, oritavancin, Pathogen, prioritized, quinupristin, request, restructuring, staffing, Synercid, telavancin, Theravance, Transplant, vancomycin, Zyvox
Filing tables
Filing exhibits
Related press release
Achillion Pharmaceuticals similar filings
Filing view
External links